Trial Profile
A Study to Evaluate the Safety, Immunogenicity and Efficacy of GlaxoSmithKline Biologicals' Candidate Malaria Vaccine RTS,S/AS02A, Administered Intramuscularly According to a 0, 1 and 2 Month Vaccination Schedule in Toddlers and Children Aged 1 to 4 Years in a Malaria-Endemic Region of Mozambique
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs GSK 257049 (Primary)
- Indications Falciparum malaria
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 11 Jun 2020 Results published in the Vaccine
- 01 Aug 2009 Results after a 45-month surveillance period have been published in the Journal of Infectious Diseases.
- 27 Mar 2009 New trial record.